371 related articles for article (PubMed ID: 29056426)
1. mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability.
Valvezan AJ; Turner M; Belaid A; Lam HC; Miller SK; McNamara MC; Baglini C; Housden BE; Perrimon N; Kwiatkowski DJ; Asara JM; Henske EP; Manning BD
Cancer Cell; 2017 Nov; 32(5):624-638.e5. PubMed ID: 29056426
[TBL] [Abstract][Full Text] [Related]
2. IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex.
Valvezan AJ; McNamara MC; Miller SK; Torrence ME; Asara JM; Henske EP; Manning BD
JCI Insight; 2020 Apr; 5(7):. PubMed ID: 32271165
[TBL] [Abstract][Full Text] [Related]
3. mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency.
Li H; Jin F; Jiang K; Ji S; Wang L; Ni Z; Chen X; Hu Z; Zhang H; Liu Y; Qin Y; Zha X
Oncotarget; 2016 May; 7(19):28435-47. PubMed ID: 27078846
[TBL] [Abstract][Full Text] [Related]
4. The mTORC1 Signaling Network Senses Changes in Cellular Purine Nucleotide Levels.
Hoxhaj G; Hughes-Hallett J; Timson RC; Ilagan E; Yuan M; Asara JM; Ben-Sahra I; Manning BD
Cell Rep; 2017 Oct; 21(5):1331-1346. PubMed ID: 29091770
[TBL] [Abstract][Full Text] [Related]
5. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.
Cao J; Tyburczy ME; Moss J; Darling TN; Widlund HR; Kwiatkowski DJ
J Clin Invest; 2017 Jan; 127(1):349-364. PubMed ID: 27918305
[TBL] [Abstract][Full Text] [Related]
6. Bcat1 is controlled by Tsc2/mTORC1 pathway at expression levels and its deficiency together with Bcat2 inactivation suppresses the growth of a Tsc2
Nishikawa K; Mezawa Y; Kobayashi T
Genes Cells; 2023 Jun; 28(6):447-456. PubMed ID: 36965015
[TBL] [Abstract][Full Text] [Related]
7. Abnormal glycogen storage in tuberous sclerosis complex caused by impairment of mTORC1-dependent and -independent signaling pathways.
Pal R; Xiong Y; Sardiello M
Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2977-2986. PubMed ID: 30728291
[TBL] [Abstract][Full Text] [Related]
8. Vps34-mediated macropinocytosis in Tuberous Sclerosis Complex 2-deficient cells supports tumorigenesis.
Filippakis H; Belaid A; Siroky B; Wu C; Alesi N; Hougard T; Nijmeh J; Lam HC; Henske EP
Sci Rep; 2018 Sep; 8(1):14161. PubMed ID: 30242175
[TBL] [Abstract][Full Text] [Related]
9. Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells.
Li J; Csibi A; Yang S; Hoffman GR; Li C; Zhang E; Yu JJ; Blenis J
Proc Natl Acad Sci U S A; 2015 Jan; 112(1):E21-9. PubMed ID: 25524627
[TBL] [Abstract][Full Text] [Related]
10. P53 suppresses ribonucleotide reductase via inhibiting mTORC1.
He Z; Hu X; Liu W; Dorrance A; Garzon R; Houghton PJ; Shen C
Oncotarget; 2017 Jun; 8(25):41422-41431. PubMed ID: 28507282
[TBL] [Abstract][Full Text] [Related]
11. Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation.
Rozas NS; Redell JB; McKenna J; Moore AN; Gambello MJ; Dash PK
Biochem Biophys Res Commun; 2015 Feb; 457(4):635-9. PubMed ID: 25613864
[TBL] [Abstract][Full Text] [Related]
12. Targeting protein homeostasis with nelfinavir/salinomycin dual therapy effectively induces death of mTORC1 hyperactive cells.
Dunlop EA; Johnson CE; Wiltshire M; Errington RJ; Tee AR
Oncotarget; 2017 Jul; 8(30):48711-48724. PubMed ID: 28415776
[TBL] [Abstract][Full Text] [Related]
13. TSC2 regulates microRNA biogenesis via mTORC1 and GSK3β.
Ogórek B; Lam HC; Khabibullin D; Liu HJ; Nijmeh J; Triboulet R; Kwiatkowski DJ; Gregory RI; Henske EP
Hum Mol Genet; 2018 May; 27(9):1654-1663. PubMed ID: 29509898
[TBL] [Abstract][Full Text] [Related]
14. Metabolomic studies identify changes in transmethylation and polyamine metabolism in a brain-specific mouse model of tuberous sclerosis complex.
McKenna J; Kapfhamer D; Kinchen JM; Wasek B; Dunworth M; Murray-Stewart T; Bottiglieri T; Casero RA; Gambello MJ
Hum Mol Genet; 2018 Jun; 27(12):2113-2124. PubMed ID: 29635516
[TBL] [Abstract][Full Text] [Related]
15. Tuberous sclerosis--A model for tumour growth.
Dodd KM; Dunlop EA
Semin Cell Dev Biol; 2016 Apr; 52():3-11. PubMed ID: 26816112
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of PERK activity and eIF2α serine 51 phosphorylation by mTOR complex 1 elicits pro-oxidant and pro-death effects in tuberous sclerosis-deficient cells.
Krishnamoorthy J; Tenkerian C; Gupta J; Ghaddar N; Wang S; Darini C; Staschke KA; Ghosh A; Gandin V; Topisirovic I; Kristof AS; Hatzoglou M; Simos G; Koromilas AE
Cell Death Dis; 2018 Feb; 9(3):254. PubMed ID: 29449538
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
[TBL] [Abstract][Full Text] [Related]
18. Tuberous sclerosis complex-associated CNS abnormalities depend on hyperactivation of mTORC1 and Akt.
Zordan P; Cominelli M; Cascino F; Tratta E; Poliani PL; Galli R
J Clin Invest; 2018 Apr; 128(4):1688-1706. PubMed ID: 29389670
[TBL] [Abstract][Full Text] [Related]
19. Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion.
Zarei M; Du H; Nassar AH; Yan RE; Giannikou K; Johnson SH; Lam HC; Henske EP; Wang Y; Zhang T; Asara J; Kwiatkowski DJ
J Exp Med; 2019 Nov; 216(11):2635-2652. PubMed ID: 31506280
[TBL] [Abstract][Full Text] [Related]
20. Decreased rates of cerebral protein synthesis measured in vivo in a mouse model of Tuberous Sclerosis Complex: unexpected consequences of reduced tuberin.
Saré RM; Huang T; Burlin T; Loutaev I; Smith CB
J Neurochem; 2018 Jun; 145(5):417-425. PubMed ID: 29364507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
